STAAR SurgicalSTAA
STAA
About: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Employees: 1,211
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
67% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 5 (+2) [Q1 2025]
19% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 57
7.68% more ownership
Funds ownership: 98.2% [Q4 2024] → 105.88% (+7.68%) [Q1 2025]
13% less funds holding
Funds holding: 211 [Q4 2024] → 184 (-27) [Q1 2025]
22% less capital invested
Capital invested by funds: $1.18B [Q4 2024] → $921M (-$254M) [Q1 2025]
45% less call options, than puts
Call options by funds: $2.76M | Put options by funds: $5M
46% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 54
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
0%
upside
Avg. target
$18
5%
upside
High target
$20
17%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Canaccord Genuity Jon Young | 17%upside $20 | Hold Maintained | 27 May 2025 |
Wells Fargo | 0%downside $17 | Equal-Weight Initiated | 21 Apr 2025 |
Stephens & Co. Mason Carrico | 0%downside $17 | Equal-Weight Reiterated | 18 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
STAAR Surgical Announces Participation in Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2025 Virtual Ophthalmology Forum Date: Tuesday, May 27, 2025 Format: Meetings and Webcast Fireside Chat Webcast: 2:00 PM ET, Webcast Link Wells Fargo 2025 West Coast Bus Tour Date: Thursday, May 29, 2025 Loca.
Neutral
Business Wire
4 weeks ago
STAAR Surgical Announces $30 Million Share Repurchase Authorization
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. “Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and.
Negative
Seeking Alpha
1 month ago
STAAR Surgical Q1: Clouded Outlook Warrants Caution (Rating Downgrade)
Sales in China were severely impacted due to inventory de-stocking, but the outlook for the region for H2 2025 looks promising. Global sales ex-China were weak, with management choosing to withdraw the earlier guidance for revenue growth of 9–15%. I expect revenue and earnings of $320 million and $23 million, respectively, for next year, which puts the current valuation at 43.5 times earnings.
Neutral
Seeking Alpha
1 month ago
STAAR Surgical Company (STAA) Q1 2025 Earnings Call Transcript
STAAR Surgical Company. (NASDAQ:STAA ) Q1 2025 Earnings Conference Call May 7, 2025 5:15 PM ET Company Participants Brian Moore - VP, Investor Relations and Corporate Development Stephen Farrell - Chair of the Board, President and CEO Warren Faust - President and COO Deborah Andrews - Interim CFO Conference Call Participants Tom Stephan - Stifel Anthony Petrone - Mizuho Ryan Zimmerman - BTIG Patrick Wood - Morgan Stanley Operator Greetings and welcome to the STAAR Surgical First Quarter 2025 Earnings Webcast.
Positive
Zacks Investment Research
1 month ago
Staar Surgical (STAA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
1 month ago
Staar Surgical (STAA) Reports Q1 Loss, Tops Revenue Estimates
Staar Surgical (STAA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.06 per share a year ago.
Neutral
Business Wire
1 month ago
STAAR Surgical Reports First Quarter 2025 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin.
Neutral
Business Wire
1 month ago
STAAR Surgical Announces Changes to Board of Directors
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has.
Neutral
Business Wire
1 month ago
STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2.
Negative
24/7 Wall Street
2 months ago
Tilman Fertitta, Carl Icahn, and More Insiders Return to the Buy Window
Since the beginning of April, market volatility has spiked, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S.
Charts implemented using Lightweight Charts™